Presentation is loading. Please wait.

Presentation is loading. Please wait.

Randomized Phase II Study of Whole-Brain Radiation Therapy with or without Concomitant Temozolomide for Brain Metastases from Breast Cancer K. I. CAO 1,

Published byEsther Brenda Todd Modified over 9 years ago

Similar presentations

Presentation on theme: "Randomized Phase II Study of Whole-Brain Radiation Therapy with or without Concomitant Temozolomide for Brain Metastases from Breast Cancer K. I. CAO 1,"— Presentation transcript:

1 Randomized Phase II Study of Whole-Brain Radiation Therapy with or without Concomitant Temozolomide for Brain Metastases from Breast Cancer K. I. CAO 1, N. LEBAS 1, S. GERBER 1, C. LEVY 2, A. FOURQUET 1, F. CAMPANA 1, R. LE SCODAN 3, B. DE LA LANDE 4, C. BOURGIER 5, J.-Y. PIERGA 1, A. GOBILLION 1, A. SAVIGNONI 1, Y. M KIROVA 1 1 INSTITUT CURIE, PARIS, FRANCE ²CENTRE FRANÇOIS BACLESSE, CAEN, FRANCE 3 CENTRE HOSPITALIER PRIVÉ SAINT-GRÉGOIRE, SAINT-GRÉGOIRE, FRANCE 4 INSTITUT CURIE, SAINT-CLOUD, FRANCE 5 INSTITUT GUSTAVE ROUSSY, VILLEJUIF, FRANCE NO DISCLOSURE

2 Main Results Primary end-point: ORR  WBRT + TMZ: 30% (n = 15)  WBRT: 36% (n = 18)  No complete response Survival  Median OS: 9.4 m WBRT + TMZ / 11.1 m WBRT  2 years – OS: 18 % (each arm)  Median PFS: 6.8 m WBRT + TMZ / 7.4 m WBRT

3 Discussion Strenghts  Prospective randomized study with long-term follow-up  Homogeneous study population (only primary breast cancer) Weaknesses  No QOL assessment  No molecular stratification  No MGMT status

4 Take home messages  WBRT combined with temozolomide did not improve brain control among patients with brain metastases from breast cancer.  WBRT remains a standard treatment in this population.  WBRT + TMZ in TNBC ? THANK YOU.

Download ppt "Randomized Phase II Study of Whole-Brain Radiation Therapy with or without Concomitant Temozolomide for Brain Metastases from Breast Cancer K. I. CAO 1,"

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
ICY THERAPY spot treats CANCER in the lung 1. Evaluating Cryoablation of Metastatic Lung/Pleura Tumors In Patients – Safety and Efficacy de Baere T 1.

ICY THERAPY spot treats CANCER in the lung 1. Evaluating Cryoablation of Metastatic Lung/Pleura Tumors In Patients – Safety and Efficacy de Baere T 1.
Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.

Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.
History of the randomized evidence on early breast cancer overall survival: Radiation vs no radiation after mastectomy L. Vakaet 2006.

History of the randomized evidence on early breast cancer overall survival: Radiation vs no radiation after mastectomy L. Vakaet 2006.
ATLAS Steering Committee: 24 September 2005 Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools.

ATLAS Steering Committee: 24 September 2005 Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools.
William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.

William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.
A pooled analysis of the final results of the two randomized phase II studies comparing Gemcitabine (G) vs Gemcitabine + Docetaxel (G+D) in patients (pts)

A pooled analysis of the final results of the two randomized phase II studies comparing Gemcitabine (G) vs Gemcitabine + Docetaxel (G+D) in patients (pts)
Phase II Design Strategies Sally Hunsberger Ovarian Cancer Clinical Trials Planning Meeting May 29, 2009.

Phase II Design Strategies Sally Hunsberger Ovarian Cancer Clinical Trials Planning Meeting May 29, 2009.
New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.

New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
Definition of oxaliplatin sensitivity in pts with advanced colorectal cancer previously treated with oxaliplatin-based therapy A. de Gramont, B. Chibaudel,

Definition of oxaliplatin sensitivity in pts with advanced colorectal cancer previously treated with oxaliplatin-based therapy A. de Gramont, B. Chibaudel,
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.

ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.
RANDOMIZED PHASE II TRIAL COMPARING FOLFIRINOX (5FU/LEUCOVORIN, IRINOTECAN AND OXALIPLATIN) VS GEMCITABINE AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC.

RANDOMIZED PHASE II TRIAL COMPARING FOLFIRINOX (5FU/LEUCOVORIN, IRINOTECAN AND OXALIPLATIN) VS GEMCITABINE AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC.
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
TREATMENT PLANNING Modelling chemo-hadron therapy Lara Barazzuol | Valencia | 19 June 2009.

TREATMENT PLANNING Modelling chemo-hadron therapy Lara Barazzuol | Valencia | 19 June 2009.
Paris- RP Reims Rennes Tours Marseille Montpellier Lyon Nice Lille Strasbourg Bordeaux Dijon Besançon Nantes Toulouse Poitiers Angers Nancy Caen Rouen.

Paris- RP Reims Rennes Tours Marseille Montpellier Lyon Nice Lille Strasbourg Bordeaux Dijon Besançon Nantes Toulouse Poitiers Angers Nancy Caen Rouen.
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.

Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
Www.OncologyEducation.com ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

Similar presentations

Ads by Google